Skip to content
EN
EN FR NL
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
Menu
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
Menu
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
Donate
BIG Members
EN
EN FR NL

Press Release

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

BIG and World Cancer Day – Together, all our actions matter

OlympiA adjuvant trial results show olaparib for BRCA 1/2 mutated and high-risk early breast cancer reduced recurrence risk by 42%

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

Breast International Group’s new Executive Board

First results of the European AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer

Metastatic breast cancer, an ultramarathon

First results of MA.32 trial: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

World Cancer Day 2022: the DECRESCENDO study

OlympiA trial – olaparib reduces risk of death by 32% in patients with a specific breast cancer profile

Page1 Page2 Page3 Page4

Breast international group (BIG) – aisbl

Rue de bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213

Facebook-f Twitter Instagram Linkedin Youtube Flickr

Navigation

  • About
  • Research
  • News
  • Support research
  • Press room
  • Contact us
  • Privacy policy
  • FAQ
AERFLABELPMSDEFVblanc

The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF

© 2022 All rights reserved

Breast international group (BIG) - aisbl